Apogee Therapeutics

Apogee management will participate in a virtual fireside chat at the Stifel 2024 #Immunology and #Inflammation Summit this month. Find details here. https://lnkd.in/epS4NGRZ

Today, we are excited to announce the appointment of Jeff Hartness as Chief Commercial Officer. As a highly accomplished leader with broad commercial expertise, we are confident Jeff will be an invaluable addition to our executive team. Read more here. https://lnkd.in/eJqkhzBp

We are excited to announce the first participants have been dosed in the Phase 1 clinical?trial of APG990, our novel, half-life extended monoclonal antibody targeting OX40L, initially being developed as a treatment for people living with #atopicdermatitis. CMO Carl Dambkowski shares insight?into this milestone below. Learn more in the press release here. https://lnkd.in/ezrSM_8c

Today, we are pleased to share several updates on our pipeline progress and report Q2 financial results. Read through highlights below and find full details in the press release here. https://lnkd.in/epcsZbS6

It's officially been one year since APGE became a publicly traded company! Thank you to our friends at Nasdaq for celebrating this milestone with us. We look forward to the growth, innovation and milestones the next year holds.

One year ago, Apogee began trading as a public company on?Nasdaq! We have made significant strides since then, moving multiple programs forward in the clinic?and getting closer to impacting millions of patients in need. We look forward to what's ahead and never stopping at "good enough."?

Today, we announced that Lisa Bollinger (Mathis), MD, has been appointed to our board of directors. Dr. Bollinger most recently served as VP, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck and has more than 30 years of experience built across global pharmaceutical companies and the #FDA, as well as her work as a pediatric physician. We are thrilled to welcome Dr. Bollinger to the A-Team! Read more below. https://lnkd.in/eYzJcNRg

We are pleased to share that members of management will participate in conferences hosted by Jefferies and Goldman Sachs in June. Learn more below. https://lnkd.in/e3DBR46f

We are pleased to announce we have initiated dosing in the Phase 2 trial of APG777 in patients with moderate-to-severe #atopicdermatitis. CEO?Michael Henderson shares more about this exciting milestone for Apogee below. Full details here. https://lnkd.in/eax5brnn

Today, we reported Q1 2024 financial results and a business update. This includes the news of our nomination of development candidate APG990, with a Phase 1 clinical trial in healthy volunteers expected to initiate ahead of schedule in 2H 2024. Additionally, we announced the initiation of a Phase 2 clinical trial of APG777 in patients with moderate-to-severe #atopicdermatitis (AD), with 16-week proof-of-concept data expected in 2H 2025. With $816M in total cash following our recent upsized follow-on offering, we now have projected cash runway into 2028. Full details here. https://lnkd.in/gCeNjuCr